Helixmith Co., Ltd
084990 | KO
Overview
Corporate Details
- ISIN(s):
- KR7084990001
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙8로7길 21, 강서구
- Website:
- https://www.helixmith.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-18 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.9 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.3 MB | ||
| 2025-07-09 00:00 |
AGM Information
임시주주총회결과
|
Korean | 6.1 KB | ||
| 2025-06-19 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 51.3 KB | ||
| 2025-06-18 00:00 |
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
|
Korean | 15.2 KB | ||
| 2025-06-18 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 48.4 KB | ||
| 2025-05-16 00:00 |
Quarterly Report
[기재정정]분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-05-15 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.0 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-05-15 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 5.7 KB | ||
| 2025-05-02 00:00 |
Legal Proceedings Report
소송등의판결ㆍ결정 (주주총회소집허가)
|
Korean | 6.2 KB | ||
| 2025-03-27 00:00 |
AGM Information
정기주주총회결과
|
Korean | 22.0 KB | ||
| 2025-03-27 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.9 MB | ||
| 2025-03-27 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 10.1 KB |
Automate Your Workflow. Get a real-time feed of all Helixmith Co., Ltd filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Helixmith Co., Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Helixmith Co., Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
United States of America
ANNX
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
South Korea
065660
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB
Romania
ATB
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
United States of America
APLS
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
United States of America
APUS
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
United States of America
APGE
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
United States of America
APLM
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Germany
APPH
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
United States of America
APLT
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060
South Korea
003060